In addition to its practical utility, the map function also reinforces the game's overarching theme of self-discovery and enlightenment. As players chart their own course through the game world, they are encouraged to embrace the spirit of adventure, curiosity, and perseverance, mirroring the journey of the legendary Monkey King himself. The map becomes not just a tool for navigation, but a metaphor for the journey of self-discovery and growth that lies at the heart of the game's narrative.In conclusion, Atlanta's encounter with Real Madrid is not just a regular match. It is an opportunity for them to showcase their progress, their skills, and their determination. Under the guidance of Lukman, Atlanta has been proving time and time again that they are a team to be reckoned with. And facing Real Madrid is just another step in their journey towards cementing their status as a footballing powerhouse.
The stage is set for a game that holds special significance for Krunic. Having spent several seasons at AC Milan, he established himself as a reliable presence in the midfield, earning the admiration of fans and teammates alike. His time at Milan was marked by memorable performances, crucial goals, and a strong bond with the club's passionate supporters.A2: Despite the opportunities, Chinese companies encounter various challenges when expanding globally. These include cultural differences, legal and regulatory hurdles, managing political risks, building brand reputation, and competing with established multinational corporations. Moreover, issues like language barriers and lack of understanding of local market dynamics can pose significant obstacles.A5: To mitigate risks, Chinese companies need to conduct thorough market research, establish solid partnerships with local businesses, comply with local regulations, and adapt their strategies to suit the cultural and business environment of the host country. Building a strong corporate governance framework, enhancing transparency, and maintaining good corporate social responsibility practices are also crucial in managing risks effectively.
One of the key challenges facing Qionghai City is the need to balance economic growth with environmental protection. Being a coastal city, Qionghai is keenly aware of the importance of sustainable development and environmental conservation. Mr. Zhou Changqiang's experience in coordinating economic development and environmental protection efforts will be instrumental in addressing this challenge.Closing marks second significant acquisition from RA Capital's Raven incubator in 2024, and first acquisition of a company built by Raven from a technology platform in-licensed from a large pharmaceutical company BOSTON , Dec. 11, 2024 /PRNewswire/ -- RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier-crossing technology that enhances delivery of targeted drugs into the central nervous system. Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), RA Capital, and Raven (RA Capital's healthcare incubator) co-founded Aliada and co-led the series seed financing in 2021 to advance the MODELTM platform created by Johnson & Johnson scientists that was licensed to Aliada at its inception. "Congratulations to the Aliada and AbbVie teams and our fellow investors on the close of this transaction," said Joshua Resnick , MD, Senior Managing Director at RA Capital Management and former board director at Aliada. "The acquisition of Aliada is the second significant acquisition of a Raven-grown company this year, joining Novartis' $1 billion upfront acquisition of radiopharmaceutical developer Mariana Oncology in May." "Delivering therapeutics across the blood-brain barrier with a low-volume, subcutaneous injection would be revolutionary for treating Alzheimer's disease and other neurological disorders, and has long been a dream in the field," said Laura Tadvalkar , PhD, Managing Director at RA Capital Management and former board chair at Aliada. "We look forward to following ALIA-1758's progress through the clinic, as AbbVie advances this important medicine for Alzheimer's disease patients." About Raven Raven is RA Capital Management's healthcare incubator. Raven's experienced team of scientists, operators, and innovators bring deep sector expertise, insight and executional capabilities across therapeutics, diagnostics, devices, and services. Raven builds companies: from originating and incubating new ideas to accelerating compelling innovations and rejuvenating promising assets. About RA Capital Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital's company creation team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 175 employees and over $10 billion in assets under management. The companies presented herein were selected to demonstrate a potential successful outcome of a company being incubated within our Raven incubator. They are not intended to represent a complete picture of RA Capital's portfolio, its exposures, risks or potential for positive or negative returns. Past performance is not indicative of future results. View original content to download multimedia: https://www.prnewswire.com/news-releases/ra-capital-management-announces-close-of-1-4-billion-acquisition-of-aliada-therapeutics-by-abbvie-302329567.html SOURCE RA Capital Management, LPEssential Properties Realty Trust, Inc. ( NYSE:EPRT – Get Free Report ) announced a quarterly dividend on Monday, December 9th, Wall Street Journal reports. Investors of record on Tuesday, December 31st will be paid a dividend of 0.295 per share on Tuesday, January 14th. This represents a $1.18 dividend on an annualized basis and a yield of 3.77%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Essential Properties Realty Trust’s previous quarterly dividend of $0.29. Essential Properties Realty Trust has raised its dividend payment by an average of 6.4% per year over the last three years. Essential Properties Realty Trust has a dividend payout ratio of 92.2% meaning its dividend is currently covered by earnings, but may not be in the future if the company’s earnings fall. Research analysts expect Essential Properties Realty Trust to earn $1.82 per share next year, which means the company should continue to be able to cover its $1.18 annual dividend with an expected future payout ratio of 64.8%. Essential Properties Realty Trust Trading Down 2.0 % NYSE:EPRT opened at $31.34 on Friday. The company has a market cap of $5.49 billion, a P/E ratio of 27.25, a price-to-earnings-growth ratio of 2.74 and a beta of 1.38. Essential Properties Realty Trust has a twelve month low of $23.58 and a twelve month high of $34.88. The business has a 50 day moving average price of $32.78 and a two-hundred day moving average price of $31.43. The company has a quick ratio of 5.59, a current ratio of 5.59 and a debt-to-equity ratio of 0.69. Analyst Ratings Changes A number of analysts recently issued reports on EPRT shares. Deutsche Bank Aktiengesellschaft started coverage on Essential Properties Realty Trust in a research report on Wednesday, December 11th. They issued a “buy” rating and a $38.00 target price on the stock. Barclays assumed coverage on Essential Properties Realty Trust in a research report on Tuesday, December 17th. They set an “overweight” rating and a $35.94 price target on the stock. Truist Financial increased their price objective on Essential Properties Realty Trust from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Scotiabank boosted their target price on shares of Essential Properties Realty Trust from $32.00 to $33.00 and gave the stock a “sector perform” rating in a report on Monday, November 25th. Finally, Evercore ISI increased their price target on shares of Essential Properties Realty Trust from $33.00 to $34.00 and gave the company an “in-line” rating in a research note on Monday, September 16th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Essential Properties Realty Trust has a consensus rating of “Moderate Buy” and a consensus target price of $33.91. View Our Latest Stock Analysis on Essential Properties Realty Trust Essential Properties Realty Trust Company Profile ( Get Free Report ) Essential Properties Realty Trust, Inc, a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. Featured Stories Receive News & Ratings for Essential Properties Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Essential Properties Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter .As the summer transfer window heats up, Liverpool FC find themselves facing potential departures of key players such as Trent Alexander-Arnold and Mohamed Salah. To combat this challenging situation, the club's attention has now shifted towards talented prospects Dusan Vlahovic and Dejan Kulusevski.
On the other side of the battlefield stood Hunter 2, a mysterious and enigmatic figure whose methods were shrouded in secrecy. Some said he possessed supernatural abilities that gave him an edge over his adversaries, while others whispered of a dark past that fueled his thirst for vengeance. Whatever the truth may be, one thing was certain – Hunter 2 was a force to be reckoned with, and his presence sent chills down the spine of even the bravest competitors.SAN FRANCISCO , Dec. 26, 2024 /PRNewswire/ -- AusperBio Therapeutics, Inc . and Ausper Biopharma Co., Ltd . (collectively AusperBio ), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B ( CHB ), today announced the successful completion of a USD 73 million Series B financing. The round was led by HanKang Capital , with participation from Sherpa Capital , CDH Investments , and a strategic investor, as well as continued participation from existing investors Qiming Venture Partners , InnoPinnacle Fund , and YuanBio Venture Capital . This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction. The proceeds will fund the continued Phase 2 development of AHB-137 , AusperBio's lead investigational therapy, supporting both clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company's therapeutic pipeline and operational capabilities to drive sustained growth. Dr. Guofeng Cheng , co-founder and CEO of AusperBio, stated, " We are honored by our investors' confidence and support. This milestone financing recognizes our scientific and clinical accomplishments to date and enables us to accelerate our clinical programs and move closer to delivering a functional cure for CHB patients in need." Dr. Chris Yang , co-founder and CSO, added, "AHB-137 continues to attract attention from the scientific and clinical communities, particularly after the late-breaking oral presentation at the recent AASLD conference. The promising clinical data further validates our Med-OligoTM platform, strengthening our development of groundbreaking targeted oligonucleotide therapies for CHB and other serious chronic diseases." AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms for this serious chronic disease. About AHB-137 AHB-137, a novel unconjugated antisense oligonucleotide ( ASO ) developed within AusperBio's proprietary Med-OligoTM ASO technology platform, was designed to treat chronic hepatitis B for a functional cure. Its compelling preclinical and Phase 1 clinical data were highlighted at the 2023 EASL conference and the 2024 EASL conference, respectively. Interim Phase 2a data was presented in a late-breaking oral session at the 2024 AASLD. This novel dual-mechanism ASO has completed its global Phase 1b trial and is now undergoing multiple Phase 2 trials in China . With its global development strategy, AHB-137 is advancing rapidly toward the goal of an HBV cure. About AusperBio. AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China , dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection. The company has developed a proprietary Med-OligoTM ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligoTM Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. For further information, please contact: Media Contact Email: info@ausperbio.com Investor Relations Contact: Tel: 650-888-1756 (US) Email: growth@ausperbio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-chronic-hepatitis-b-302339451.html SOURCE AusperBio Therapeutics Inc.
BINGHAMTON, N.Y. (AP) — Chris Walker scored 22 points as Binghamton beat Lancaster Bible 85-60 on Sunday. Walker shot 7 for 8 (4 for 5 from 3-point range) and 4 of 6 from the free-throw line for the Bearcats (6-6). Ben Callahan-Gold added 13 points while going 5 of 9 (3 for 6 from 3-point range) while he also had five rebounds. Tymu Chenery shot 5 of 11 from the field, including 1 for 7 from 3-point range, and went 1 for 4 from the line to finish with 12 points. The Chargers were led in scoring by Reaves Hooks, who finished with 15 points. Jordan Praylow added 10 points and three steals for Lancaster Bible. Camden Hurst also recorded nine points. Binghamton hosts Mercyhurst in its next matchup on Wednesday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .The Argentina team has been riding a wave of success, with key players leading the charge on both the international and club fronts. Lionel Messi and Rodrigo De Paul, the midfield duo representing Argentina, have been instrumental in their team's impressive performances. Messi, who recently transferred to Paris Saint-Germain, has continued to showcase his exceptional skills and leadership on the field. His presence has undoubtedly elevated the overall quality of the Argentina team, providing invaluable experience and expertise.